R01 CA163793/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2013	1
2014	2
2015	3
2016	6
2017	3
2018	2
2019	3
2021	0

1

The future of immune checkpoint therapy.

Sharma P, Allison JP. Sharma P, et al. Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172. Science. 2015. PMID: 25838373 Review.

2

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Sharma P, et al. Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017. Cell. 2017. PMID: 28187290 Free PMC article. Review.

3

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP. Wei SC, et al. Cell. 2017 Sep 7;170(6):1120-1133.e17. doi: 10.1016/j.cell.2017.07.024. Epub 2017 Aug 10. Cell. 2017. PMID: 28803728 Free PMC article.

4

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Sharma P, Allison JP. Sharma P, et al. Cell. 2015 Apr 9;161(2):205-14. doi: 10.1016/j.cell.2015.03.030. Cell. 2015. PMID: 25860605 Free PMC article. Review.

5

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.

Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. Gao J, et al. Nat Med. 2017 May;23(5):551-555. doi: 10.1038/nm.4308. Epub 2017 Mar 27. Nat Med. 2017. PMID: 28346412 Free PMC article.

6

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Gao J, et al. Cell. 2016 Oct 6;167(2):397-404.e9. doi: 10.1016/j.cell.2016.08.069. Epub 2016 Sep 22. Cell. 2016. PMID: 27667683 Free PMC article.

7

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3⁺ Regulatory T Cells (Tregs) in Human Cancers.

Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Sharma A, et al. Clin Cancer Res. 2019 Feb 15;25(4):1233-1238. doi: 10.1158/1078-0432.CCR-18-0762. Epub 2018 Jul 27. Clin Cancer Res. 2019. PMID: 30054281 Free PMC article.

8

Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.

Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Blando J, et al. Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692-1697. doi: 10.1073/pnas.1811067116. Epub 2019 Jan 11. Proc Natl Acad Sci U S A. 2019. PMID: 30635425 Free PMC article.

9

Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy.

Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Goswami S, et al. J Clin Invest. 2018 Aug 31;128(9):3813-3818. doi: 10.1172/JCI99760. Epub 2018 Jul 30. J Clin Invest. 2018. PMID: 29905573 Free PMC article.

10

Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.

Shi LZ, Goswami S, Fu T, Guan B, Chen J, Xiong L, Zhang J, Ng Tang D, Zhang X, Vence L, Blando J, Allison JP, Collazo R, Gao J, Sharma P. Shi LZ, et al. Cancer Immunol Res. 2019 Nov;7(11):1803-1812. doi: 10.1158/2326-6066.CIR-18-0873. Epub 2019 Aug 29. Cancer Immunol Res. 2019. PMID: 31466995 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results